File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

TitleAdvances in clinical NK cell studies: Donor selection, manufacturing and quality control
Authors
Koehl, U.Kalberer, C.Spanholtz, J.Lee, D. A.Miller, J. S.Cooley, S.Lowdell, M.Uharek, L.Klingemann, H.Curti, A.Leung, W.Alici, E.
Keywordsex vivo expansion
quality control
manufacturing of NK cell products
Clinical NK cell studies
Issue Date2016
Citation
OncoImmunology, 2016, v. 5, n. 4, article no. e1115178 How to Cite?
DOI: http://dx.doi.org/10.1080/2162402X.2015.1115178
AbstractNatural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.
Persistent Identifierhttp://hdl.handle.net/10722/294515
ISSN
2162-4011
2014 Impact Factor: 6.266
2023 SCImago Journal Rankings: 2.345
PubMed Central ID
PMC4839369
ISI Accession Number ID
WOS:000374194200028

 

DC FieldValueLanguage
dc.contributor.authorKoehl, U.-
dc.contributor.authorKalberer, C.-
dc.contributor.authorSpanholtz, J.-
dc.contributor.authorLee, D. A.-
dc.contributor.authorMiller, J. S.-
dc.contributor.authorCooley, S.-
dc.contributor.authorLowdell, M.-
dc.contributor.authorUharek, L.-
dc.contributor.authorKlingemann, H.-
dc.contributor.authorCurti, A.-
dc.contributor.authorLeung, W.-
dc.contributor.authorAlici, E.-
dc.date.accessioned2020-12-03T08:22:54Z-
dc.date.available2020-12-03T08:22:54Z-
dc.date.issued2016-
dc.identifier.citationOncoImmunology, 2016, v. 5, n. 4, article no. e1115178-
dc.identifier.issn2162-4011-
dc.identifier.urihttp://hdl.handle.net/10722/294515-
dc.description.abstractNatural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.-
dc.languageeng-
dc.relation.ispartofOncoImmunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectex vivo expansion-
dc.subjectquality control-
dc.subjectmanufacturing of NK cell products-
dc.subjectClinical NK cell studies-
dc.titleAdvances in clinical NK cell studies: Donor selection, manufacturing and quality control-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1080/2162402X.2015.1115178-
dc.identifier.pmid27141397-
dc.identifier.pmcidPMC4839369-
dc.identifier.scopuseid_2-s2.0-84962886163-
dc.identifier.volume5-
dc.identifier.issue4-
dc.identifier.spagearticle no. e1115178-
dc.identifier.epagearticle no. e1115178-
dc.identifier.eissn2162-402X-
dc.identifier.isiWOS:000374194200028-
dc.identifier.issnl2162-4011-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats